Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer

British Journal of Cancer

Volumn 93, Issue 4, 2005, Pages 453-457

  Boldrini, L ^a   Donati, V ^a   Dell'Omodarme, M ^b   Prati, M C ^b   Faviana, P ^a   Camacci, T ^a   Lucchi, M ^a   Mussi, A ^a   Santoro, M ^c   Basolo, F ^a   Fontanini, G ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INFN SEZIONE DI PISA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Disease free survival; Immunohistochemistry (IHC); Non small cell lung cancer (NSCLC); Osteopontin (OPN); Overall survival

Indexed keywords

OSTEOPONTIN; TUMOR MARKER; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE MARKER; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; STATISTICAL SIGNIFICANCE; BIOSYNTHESIS; CHEMISTRY; DISEASE FREE SURVIVAL; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 24944486451     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602715     Document Type: Article

References (25)

1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521
2. Armitage P, Berry G, Matthews JNS (2002) Statistical Methods in Medical Research. Oxford, UK: Blackwell Publishing
3. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG (1996) Osteopontin expression in lung cancers. Lung Cancer 15: 311-323
4. Coppola D, Szabo M, Boulware D, Muraca P, Alsarra M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190
5. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest 107: 1055-1061
6. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1: 621-632
7. Giachelli CM, Steitz S (2000) Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19: 615-622
8. Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526
9. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287: 1671-1679
10. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710-1717
11. Oates AJ, Barraclough R, Rudland PS (1997) The role of osteopontin in tumorigenesis and metastasis. Invas Metast 17: 1-15
12. R Development Core Team (2003) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing
13. Reinholt FP, Hultenby K, Oldberg A, Heinegard D (1990) Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 87: 4473-4475
14. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH, Danenberg PV (2004) Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small lung cancer. Clin Cancer Res 10: 1588-1596
15. Shijubo N, Uede T, Kon S, Maeda K, Segawa T, Imado A, Hirasawa H, Abe S (1999) Vascular endothelial growth factor in stage I lung adenocarcinoma. Am J Resp Crit Care Med 160: 1269-1273
16. Shijubo N, Uede T, Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncol 11: 135-146
17. Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral Biol Med 11: 279-303
18. Sorensen ES, Hojruo P, Petersen TE (1995) Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosilation sites. Protein Sci 4: 2040-2049
19. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5: 2271-2277
20. Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mamm Gland Biol Neoplasia 6: 419-429
21. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121: 578-584
22. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E (1998) Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79: 127-132
23. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochem Biophys Acta 1552: 61-85
24. World Health Organization (1982) Histological typing of lung tumours. Am J Clin Pathol 77: 123-136
25. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K, Fukuchi Y (2001) Differential osteopontin expression in lung cancer. Cancer Lett 171: 215-222